NCT03612986 (SMILE) is a NA clinical trial of SYALOX® 300 Plus in Knee Osteoarthritis, sponsored by River Pharma S.r.l..

Who is sponsoring NCT03612986?

NCT03612986 is sponsored by River Pharma S.r.l..

What drugs are being tested in NCT03612986?

Interventions in NCT03612986: SYALOX® 300 Plus, Placebo.

What condition does NCT03612986 study?

NCT03612986 studies Knee Osteoarthritis.

Is NCT03612986 still recruiting?

NCT03612986 is currently completed. Last updated 2 October 2019.

Last reviewed 2019-10-02 · How we verify

NCT03612986: SMILE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Trial to Evaluate the Effects of a Nutraceutical in Patients Affected by Knee Osteoarthritis

Completed NA Last updated 2 October 2019

What this trial tests

NA trial testing SYALOX® 300 Plus in Knee Osteoarthritis in 72 participants. Completed in 26 July 2019.

Timeline

22 August 2018

Primary endpoint
10 April 2019

26 July 2019

Quick facts

Lead sponsor	River Pharma S.r.l.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	72
Start date	22 August 2018
Primary completion	10 April 2019
Estimated completion	26 July 2019
Sites	1 location across Romania

Drugs / interventions tested

SYALOX® 300 Plus
Placebo

Conditions studied

Knee Osteoarthritis — all drugs for Knee Osteoarthritis →

Sponsor

River Pharma S.r.l.

Who can join

Adults 45 to 70, any sex, with Knee Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Double blind, placebo controlled trial to evaluate the effects of a nutraceutical containing high-molecular-weight hyaluronic acid (HA) and acetyl-11-keto-beta-boswellicacid (AKBA) in patients affected by knee osteoarthritis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Knee Osteoarthritis

Currently open trials in the same condition.

NCT06906939 — A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression · EARLY_PHASE1 · recruiting
NCT05823727 — Effects of Collagen Peptide Supplementation on Connective Tissue Remodeling, Functional Outcomes, and Wound Healing Afte · NA · recruiting
NCT07370480 — Knee Osteoarthritis and Thermal Spa Treatment · NA · recruiting
NCT07507175 — Gastrocnemius Myofascial Release in Females With Knee Osteoarthritis · NA · recruiting
NCT07386600 — Dexamethasone vs Dexmedetomidine for iPACK + ACB in TKA · NA · recruiting

Other River Pharma S.r.l. trials

Trials by the same sponsor.

NCT03421054 — Pilot Trial to Assess the Feasibility of Implementing Objective Parameters in Patients Affected by Knee Osteoarthritis · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03612986 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by River Pharma S.r.l.
Last refreshed: 2 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03612986.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing